Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience. - Choucair K; Page SJ; Mattar BI; Dakhil CS; Nabbout NH; Deutsch JM; Truong QV; Truong PV; Moore DF Jr; Cannon MW; Kallail KJ; Moore JA; et al. (Clinical breast cancer, 2023)